Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors Meeting Abstract
| Authors: | Zamarin, D.; Hamid, O.; Nayak, A.; Sahebjam, S.; Sznol, M.; Collaku, A.; Fox, F.; Marshall, M.; Hong, D. |
| Abstract Title: | Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors |
| Meeting Title: | 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 6 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Nov 7-11 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2018-11-06 |
| Start Page: | 115 |
| Language: | English |
| PMCID: | PMC6220479 |
| PUBMED: | 30400822 |
| DOI: | 10.1186/s40425-018-0423-x |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: O19 |
